State Street Corp Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

State Street Corp increased its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 101.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 821,131 shares of the company's stock after acquiring an additional 413,425 shares during the period. State Street Corp owned about 2.77% of Dianthus Therapeutics worth $22,483,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its holdings in shares of Dianthus Therapeutics by 40.5% during the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company's stock valued at $25,936,000 after purchasing an additional 273,670 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in Dianthus Therapeutics by 151.3% in the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company's stock valued at $11,984,000 after acquiring an additional 263,500 shares during the period. Great Point Partners LLC boosted its position in Dianthus Therapeutics by 21.3% in the second quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock worth $19,615,000 after purchasing an additional 132,929 shares during the last quarter. Braidwell LP grew its stake in shares of Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company's stock valued at $13,517,000 after purchasing an additional 126,836 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company's stock valued at $4,543,000 after purchasing an additional 97,362 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a report on Friday. They issued a "buy" rating on the stock. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Finally, Oppenheimer raised their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $46.43.

Dianthus Therapeutics Stock Down 2.6 %

DNTH stock traded down $0.62 during trading on Monday, reaching $23.18. The company's stock had a trading volume of 158,385 shares, compared to its average volume of 205,606. The company's fifty day moving average is $25.65 and its 200-day moving average is $26.69. The company has a market capitalization of $686.13 million, a P/E ratio of -9.27 and a beta of 1.74. Dianthus Therapeutics, Inc. has a 1 year low of $10.02 and a 1 year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.07 million. Analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.